Bulletin
Investor Alert

press release

Jan. 4, 2022, 8:01 a.m. EST

Replimune to Present at the 40th Annual J.P. Morgan Healthcare Conference

WOBURN, Mass., Jan 04, 2022 (GLOBE NEWSWIRE via COMTEX) -- WOBURN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. /zigman2/quotes/203971249/composite REPL +1.39% , a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 40 [th] Annual J.P. Morgan Healthcare Conference being held virtually on Monday, January 10, 2022 at 7:30 AM ET.

A simultaneous webcast will be available in the Investors section of Replimune's website at www.replimune.com . A replay will be available for 30 days following the conference.

About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune's proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform has a unique dual local and systemic mechanism of action (MOA) consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment (TME) to ignite a strong and durable systemic response. This MOA is expected to be synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com .

Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Lissette Steele
Verge Scientific Communications
202.930.4762 x 409
lsteele@vergescientific.com

COMTEX_400021174/2471/2022-01-04T08:00:30

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2022 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/203971249/composite
US : U.S.: Nasdaq
$ 19.67
+0.27 +1.39%
Volume: 430,868
Nov. 29, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$964.94 million
Rev. per Employee
N/A
loading...

Partner Center

Link to MarketWatch's Slice.